LONDON—Automata, a pioneering lab automation company developing fully integrated, AI-ready platforms for the life sciences sector, has announced the successful closing of a $45 million Series C funding round. The round was led by Dimension, with significant participation from Danaher Ventures, Tru Arrow Partners, Octopus Ventures, and Entrepreneurs First. The investment marks a major milestone in the company’s mission to revolutionize laboratory workflows through intelligent automation and seamless integration with artificial intelligence. A key element of this funding round is a strategic partnership with Danaher Corporation, a global leader in scientific instruments and life sciences technologies. As part of the collaboration, Murali Venkatesan, Ph.D., Global Head of Danaher Ventures and Vice President of Science at Danaher, will join Automata’s board of directors. This alliance underscores Danaher’s confidence in Automata’s vision and its potential to accelerate innovation in research and development across pharmaceuticals, biotechnology, and academic institutions. Automata’s platforms are designed to bring end-to-end automation to laboratory environments, enabling researchers to streamline complex workflows such as sample preparation, assay execution, and data collection. What sets the company apart is its focus on building systems that are not only automated but also inherently AI-ready—meaning they generate structured, high-quality data that can be directly fed into machine learning models. This integration allows for real-time insights, predictive analytics, and continuous optimization of experiments, significantly reducing human error and accelerating discovery timelines. The new capital will be used to scale operations, expand product development, and deepen integration with AI and machine learning tools. Automata plans to enhance its platform’s adaptability across diverse research domains, including drug discovery, genomics, and synthetic biology. The company is also investing in expanding its team, particularly in engineering, data science, and customer success, to support growing demand from biotech firms and research institutions. The Series C funding comes at a pivotal moment in the life sciences industry, where automation and AI are increasingly seen as essential to overcoming bottlenecks in R&D. With the average drug development cycle lasting over a decade and costing billions, companies are under intense pressure to innovate faster. Automata’s AI-integrated automation offers a path to more efficient, reproducible, and data-driven research. The investment reflects growing investor confidence in the convergence of automation and artificial intelligence in scientific discovery. Dimension, known for backing transformative technology companies, cited Automata’s strong technical foundation and market potential as key drivers of its participation. Danaher Ventures, with its deep expertise in scientific innovation and commercialization, sees the partnership as a strategic move to strengthen its ecosystem of next-generation research tools. This funding round follows earlier investments from top-tier venture firms and accelerates Automata’s journey toward becoming a foundational platform for intelligent laboratories. As the demand for faster, smarter, and more scalable research solutions grows, Automata is positioning itself at the forefront of a new era in life sciences—where automation and AI work in tandem to unlock scientific breakthroughs. With the support of industry leaders like Danaher and a growing network of strategic partners, Automata is poised to redefine how laboratories operate, making advanced research more accessible, efficient, and impactful across the global scientific community.